Alexander Zehnder, CureVac CEO (via website)
CureVac claims delay in German court over alleged infringement of its Covid-19 vaccine by BioNTech a sign in its favor
CureVac is expecting good news in its patent infringement cases for components of its Covid-19 vaccine against Pfizer partner BioNTech in Germany after a court …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.